525 related articles for article (PubMed ID: 17208284)
1. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
[TBL] [Abstract][Full Text] [Related]
3. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
5. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
6. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
[TBL] [Abstract][Full Text] [Related]
7. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET for management of cervical and ovarian cancer.
Havrilesky LJ; Kulasingam SL; Matchar DB; Myers ER
Gynecol Oncol; 2005 Apr; 97(1):183-91. PubMed ID: 15790456
[TBL] [Abstract][Full Text] [Related]
9. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
[TBL] [Abstract][Full Text] [Related]
10. [The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma].
Grabiec M; Walentowicz M; Nowicki P
Ginekol Pol; 2006 Oct; 77(10):746-52. PubMed ID: 17219805
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
12. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
García Velloso MJ; Boán García JF; Villar Luque LM; Aramendía Beitia JM; López García G; Richter Echeverría JA
Rev Esp Med Nucl; 2003; 22(4):217-23. PubMed ID: 12846945
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer.
Cho SM; Ha HK; Byun JY; Lee JM; Kim CJ; Nam-Koong SE; Lee JM
AJR Am J Roentgenol; 2002 Aug; 179(2):391-5. PubMed ID: 12130439
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review.
Makhija S; Howden N; Edwards R; Kelley J; Townsend DW; Meltzer CC
Gynecol Oncol; 2002 Apr; 85(1):53-8. PubMed ID: 11925120
[TBL] [Abstract][Full Text] [Related]
16. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer.
Nakamoto Y; Saga T; Ishimori T; Mamede M; Togashi K; Higuchi T; Mandai M; Fujii S; Sakahara H; Konishi J
AJR Am J Roentgenol; 2001 Jun; 176(6):1449-54. PubMed ID: 11373212
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
19. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac.
Díaz-Montes TP; Jacene HA; Wahl RL; Bristow RE
Gynecol Oncol; 2005 Sep; 98(3):510-2. PubMed ID: 15992914
[TBL] [Abstract][Full Text] [Related]
20. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
